Cargando…

Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients

Hematuria—either macroscopic hematuria or asymptomatic microscopic hematuria—is a clinical feature typical but not specific for immunoglobulin A nephropathy (IgAN). The only biomarker supported by the Kidney Disease: Improving Global Outcomes group as a predictor of progression, identifying patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zand, Ladan, Fervenza, Fernando C, Coppo, Rosanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	CKJ Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695511/ http://dx.doi.org/10.1093/ckj/sfad232

Ejemplares similares

PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations
por: Casal Moura, Marta, et al.
Publicado: (2022)

Future landscape for the management of membranous nephropathy
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2023)

Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
por: Ebbestad, Robin, et al.
Publicado: (2022)

IgAN Genetic Risk Score in the Clinical Setting
por: Schena, Francesco Paolo, et al.
Publicado: (2020)

New directions in the pathogenesis of primary erythrocytosis in IgAN
por: Schena, Francesco Paolo, et al.
Publicado: (2022)

Targeting complement in IgA nephropathy
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2023)

The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2023)

Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN)
por: De Angelis, Maria, et al.
Publicado: (2014)

Proteomic signature of tubulointerstitial tissue predicts prognosis in IgAN
por: Paunas, Flavia Teodora Ioana, et al.
Publicado: (2022)

Immune abnormalities in IgA nephropathy
por: Gentile, Micaela, et al.
Publicado: (2023)

Expanding options of supportive care in IgA nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2023)

Systemic and targeted steroids for the treatment of IgA nephropathy
por: Locatelli, Francesco, et al.
Publicado: (2023)

Identification of key cuproptosis-related genes and their targets in patients with IgAN
por: Lin, Huagang, et al.
Publicado: (2022)

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
por: Hafez, Gaye, et al.
Publicado: (2023)

Citation classics: ranking of the top 100 most cited articles in nephrology
por: Montinaro, Vincenzo, et al.
Publicado: (2018)

The new Clinical Kidney Journal, 4 years later
por: Ortiz, Alberto, et al.
Publicado: (2019)

Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis
por: Lee, Mingfeng, et al.
Publicado: (2023)

An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
por: Zand, Ladan, et al.
Publicado: (2019)

Understanding patient needs and predicting outcomes in IgA nephropathy using data analytics and artificial intelligence: a narrative review
por: Schena, Francesco Paolo, et al.
Publicado: (2023)

The Role of Renal Macrophage, AIM, and TGF-β1 Expression in Renal Fibrosis Progression in IgAN Patients
por: Yang, Min, et al.
Publicado: (2021)

Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
por: Vervloet, Marc G
Publicado: (2023)

Management of traditional risk factors for the development and progression of chronic kidney disease
por: Lo, Robin, et al.
Publicado: (2023)

Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis
por: Pisano, Anna, et al.
Publicado: (2021)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

MicroRNAs: emerging biomarkers and therapeutic targets of bone fragility in chronic kidney disease
por: Smout, Dieter, et al.
Publicado: (2022)

Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology
por: Junho, Carolina Victoria Cruz, et al.
Publicado: (2023)

Partnering with patients and caregivers to enrich research and care in kidney disease: values and strategies
por: Cazzolli, Rosanna, et al.
Publicado: (2023)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
por: Leoncini, Giovanna, et al.
Publicado: (2022)

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
por: Rizk, Dana V., et al.
Publicado: (2023)

Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
por: Schimpf, Judith Isabel, et al.
Publicado: (2018)

Decreased Expression of Urinary Mammalian Target of Rapamycin mRNA Is Related to Chronic Renal Fibrosis in IgAN
por: Cao, Yuhan, et al.
Publicado: (2019)

Chemokine (C–C motif) receptor 2 is associated with the pathological grade and inflammatory response in IgAN children
por: Shen, Yanjie, et al.
Publicado: (2022)

APOC1 exacerbates renal fibrosis through the activation of the NF-κB signaling pathway in IgAN
por: Yu, Kuipeng, et al.
Publicado: (2023)

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy
por: Yang, Joshua Y. C., et al.
Publicado: (2019)

The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease
por: Hui, Gar Kay, et al.
Publicado: (2015)

P01-029 – Microscopic hematuria in FMF
por: Grabowitz, L, et al.
Publicado: (2013)

WCN23-1022 Persistent microscopic hematuria in IgA nephropathy and frequency of gross hematuria following SARS-CoV-2 mRNA vaccination
por: YOKOTE, S., et al.
Publicado: (2023)

Recurrence of immunoglobulin A nephropathy after kidney transplantation: a narrative review of the incidence, risk factors, pathophysiology and management of immunosuppressive therapy
por: Infante, Barbara, et al.
Publicado: (2020)

The genetic map of diabetic nephropathy: evidence from a systematic review and meta-analysis of genetic association studies
por: Tziastoudi, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tpkiu34cfjuahp3ava8tbbjclc